Peginterferon α-2a plus ribavirin in latino and non-latino whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO study

American Journal of Gastroenterology

Volumn 105, Issue 10, 2010, Pages 2177-2185

  Balart, Luis A ^a   Lisker Melman, Mauricio ^b   Hamzeh, Fayez M ^c   Kwok, Ambrose ^d   Lentz, Ellen ^c   Rodriguez Torres, Maribel ^e  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d Everest Clinical Research Services   (Canada)

^e Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASIAN INFLUENZA; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HISTOLOGY; HUMAN; HUMAN CELL; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HISPANIC AMERICANS; HUMANS; INTERFERON ALFA-2A; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77957832921     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.157     Document Type: Article

References (22)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitisC virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62. (Pubitemid 29384163)
2. Bonacini M, Groshen MD, Yu MC et al. Chronic hepatitis C in ethnicminority patients evaluated in Los Angeles County. Am J Gastroenterol 2001; 96: 2438-41. (Pubitemid 32769208)
3. Verma S, Bonacini M, Govindarajan S et al. More advanced hepatic fibrosisin hispanics with chronic hepatitis C infection: role of patient demographics,hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006; 101: 1817-23. (Pubitemid 44166592)
4. Wise M, Bialek S, Finelli L et al. Changing trends in hepatitis C-relatedmortality in the United States, 1995-2004. Hepatology 2008; 47: 1128-35.
5. Rodríguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 2008; 6: 484-90. (Pubitemid 351609457)
6. Brown RS, Jacobson IM, Afdhal N. Differences in treatment outcome to antiviraltherapy based on genotype and viral load in hepatitis C genotypes 2and 3 in the WIN-R trial. Digestive Diseases Week. Los Angeles, CA, 2006
7. Cheung RC, Currie S, Shen H et al. Chronic hepatitis C in Latinos: naturalhistory, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005; 100: 2186-93. (Pubitemid 43919717)
8. Gaglio PJ, Rodríguez-Torres M, Herring R et al. Racial differences inresponse rates to consensus interferon in HCV infected patients naive toprevious therapy. J Clin Gastroenterol 2004; 38: 599-604. (Pubitemid 38955419)
9. Hepburn MJ, Hepburn LM, Cantu NS et al. Differences in treatment outcomefor hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
10. Rodríguez-Torres M, Jeffers LJ, Sheikh MY et al. Peginterferon alfa-2a andribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-67.
11. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging ofchronic hepatitis. J Hepatol 1995; 22: 696-9.
12. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis Cvirus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14. (Pubitemid 46780630)
13. Rodríguez-Torres M, Ríos-Bedoya CF, Rodríguez-Orengo J et al. Progressionto cirrhosis in Latinos with chronic hepatitis C: differences in PuertoRicans with and without human immunodeficiency virus coinfection andalong gender. J Clin Gastroenterol 2006; 40: 358-66. (Pubitemid 44309530)
14. Everson GT, Balart L, Lee SS et al. Histological benefits of virologicalresponse to peginterferon alfa-2a monotherapy in patients with hepatitis Cand advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-51. (Pubitemid 351316789)
15. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response tointerferon-α is associated with improved outcome in HCV-related cirrhosis:a retrospective study. Hepatology 2007; 45: 579-87. (Pubitemid 46453759)
16. Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic responseand clinical outcomes in patients with chronic hepatitis C and advancedfibrosis. Ann Intern Med 2007; 147: 677-84. (Pubitemid 351664462)
17. Harrison SA, Brunt EM, Qazi RA et al. Effect of significant histologicsteatosis or steatohepatitis on response to antiviral therapy in patientswith chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 604-9.
18. Zeuzem S. Heterogeneous virologic response rates to interferon- basedtherapy in patients with chronic hepatitis C: who responds less well? AnnIntern Med 2004; 140: 370-81. (Pubitemid 38268917)
19. Everson GT, Hoefs JC, SeeffLB et al. Impact of disease severity on outcomeof antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial.Hepatology 2006; 44: 1675-84.
20. Rahman F, Rehermann B. Ethnicity and hepatitis C virus infection. ClinGastroenterol Hepatol 2004; 2: 456-8. (Pubitemid 38698358)
21. Daniel S. Chronic hepatitis C treatment patterns in African Americanpatients: an update. Am J Gastroenterol 2005; 100: 716-22. (Pubitemid 40487574)
22. Layden-Almer JE, Ribeiro RM, Wiley T et al. Viral dynamics andresponse differences in HCV-infected African American and whitepatients treated with IFN and ribavirin. Hepatology 2003; 37:1343-50. (Pubitemid 36667314)